BAM
VRTX icon

Belpointe Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Belpointe Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86M Buy
3,741
+965
+35% +$428K 0.06% 296
2026
Q1 		$1.24M Sell
2,776
-1,404
-34% -$655K 0.05% 377
2025
Q4 		$1.9M Sell
4,180
-55
-1% -$23.7K 0.07% 236
2025
Q3 		$1.66M Buy
4,235
+455
+12% +$190K 0.06% 266
2025
Q2 		$1.68M Sell
3,780
-225
-6% -$104K 0.07% 233
2025
Q1 		$1.94M Buy
4,005
+2,784
+228% +$1.3M 0.1% 186
2024
Q4 		$605K Sell
1,221
-26
-2% -$12.1K 0.04% 466
2024
Q3 		$580K Buy
1,247
+145
+13% +$69.7K 0.03% 467
2024
Q2 		$517K Buy
1,102
+76
+7% +$33K 0.04% 449
2024
Q1 		$429K Buy
1,026
+297
+41% +$126K 0.03% 474
2023
Q4 		$297K Buy
729
+50
+7% +$18.5K 0.03% 524
2023
Q3 		$236K Sell
679
-240
-26% -$83.9K 0.02% 554
2023
Q2 		$323K Sell
919
-595
-39% -$200K 0.03% 423
2023
Q1 		$477K Sell
1,514
-3,351
-69% -$1.01M 0.03% 585
2022
Q4 		$1.4M Sell
4,865
-2,062
-30% -$628K 0.08% 242
2022
Q3 		$2.01M Buy
6,927
+1,593
+30% +$458K 0.14% 157
2022
Q2 		$1.5M Sell
5,334
-334
-6% -$89.4K 0.1% 215
2022
Q1 		$1.48M Sell
5,668
-310
-5% -$73.6K 0.09% 239
2021
Q4 		$1.29M Buy
5,978
+281
+5% +$54.6K 0.08% 252
2021
Q3 		$1.03M Buy
5,697
+258
+5% +$50.4K 0.07% 302
2021
Q2 		$1.1M Buy
5,439
+897
+20% +$188K 0.08% 272
2021
Q1 		$976K Buy
4,542
+3,449
+316% +$758K 0.08% 258
2020
Q4 		$258K Buy
1,093
+354
+48% +$81.2K 0.02% 620
2020
Q3 		$201K Sell
739
-1,259
-63% -$347K 0.02% 548
2020
Q2 		$580K Buy
1,998
+296
+17% +$80.3K 0.08% 269
2020
Q1 		$405K Sell
1,702
-1,164
-41% -$267K 0.07% 280
2019
Q4 		$628K Buy
+2,866
New +$580K 0.08% 276

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Belpointe Asset Management's VRTX Position: Q2 2026 in Review

Belpointe Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 35% in Q2 2026, buying an estimated $428K and bringing the position to 3,741 shares worth $1.86M. The position accounts for 0.06% of the portfolio, ranked #296.

Belpointe Asset Management first reported a position in VRTX in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.01M in Q3 2022. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Belpointe Asset Management held 3,741 shares of Vertex Pharmaceuticals worth $1.86M as of Q2 2026.
  • Belpointe Asset Management bought 965 Vertex Pharmaceuticals shares in Q2 2026, an estimated $428K.
  • Vertex Pharmaceuticals made up 0.06% of Belpointe Asset Management's portfolio in Q2 2026, its #296 holding.
  • Belpointe Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Belpointe Asset Management's Vertex Pharmaceuticals position peaked at $2.01M in Q3 2022.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.